Endovascular Treatment of Patients With Acute Ischemic Stroke With Tandem Lesions Presenting With Low Alberta Stroke Program Early Computed Tomography Score
Galecio-Castillo M, Farooqui M, Guerrero W, Ribo M, Hassan A, Jumaa M, Divani A, Abraham M, Petersen N, Fifi J, Malik A, Siegler J, Nguyen T, Sheth S, Linares G, Janjua N, Soomro J, Quispe-Orozco D, Olivé-Gadea M, Tekle W, Zaidi S, Sabbagh S, Barkley T, Prasad A, De Leacy R, Abdalkader M, Salazar-Marioni S, Gordon W, Turabova C, Rodriguez-Calienes A, Dibas M, Mokin M, Yavagal D, Yoo A, Sarraj A, Jovin T, Ortega-Gutierrez S. Endovascular Treatment of Patients With Acute Ischemic Stroke With Tandem Lesions Presenting With Low Alberta Stroke Program Early Computed Tomography Score. Journal Of The American Heart Association 2024, 13: e035977. PMID: 39508172, PMCID: PMC11681390, DOI: 10.1161/jaha.124.035977.Peer-Reviewed Original ResearchLower Alberta Stroke Program Early Computed Tomography ScoreAlberta Stroke Program Early Computed Tomography ScoreModified Rankin ScaleComputed tomography scoreSymptomatic intracranial hemorrhageEndovascular thrombectomyIntracranial hemorrhageTandem lesionsBaseline Alberta Stroke Program Early Computed Tomography ScoreAnterior circulation tandem lesionsModified Rankin Scale shiftModified Rankin Scale 0 to 2Score 0 to 2Safety of endovascular thrombectomySymptomatic intracranial hemorrhage riskOdds of symptomatic intracranial hemorrhageEndovascular treatment of patientsAcute large-vessel occlusionInternal carotid artery stenosis/occlusionIntracranial hemorrhage riskRetrospective analysis of dataProportion of patientsTreatment of patientsOrdinal modified Rankin ScaleAssociated with reduced oddsPreventing Long-Term Neurologic Disability in Hemophilia (A): Cost-Effectiveness of Emicizumab Prophylaxis for the Prevention of Intracranial Hemorrhage in Infants with Severe Hemophilia (A)
Glaeser-Khan S, Richmond R, Ito S, Bona R, Krumholz H, Cuker A, Goshua G. Preventing Long-Term Neurologic Disability in Hemophilia (A): Cost-Effectiveness of Emicizumab Prophylaxis for the Prevention of Intracranial Hemorrhage in Infants with Severe Hemophilia (A). Blood 2024, 144: 157-157. DOI: 10.1182/blood-2024-203690.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioStandard-of-careStandard half-lifeEmicizumab prophylaxisSevere hemophilia AIntracranial hemorrhageIntracranial hemorrhage incidenceSevere HAHemophilia AProbabilistic sensitivity analysesYears of agePrevention of intracranial hemorrhageNeurological disabilityPrevent intracranial hemorrhageIntracranial hemorrhage eventsIntracranial hemorrhage riskPhase III studyBase-casePersistent neurological disabilityAged 1 monthFactor VIII replacementStandard-of-care armUS societal perspectiveInfants Aged 0Aged 0Risk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset
Hu J, Chandler M, Manuel C, Caicedo J, Denne M, Ewenstein B, Mokdad A, Xing S, Recht M. Risk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset. Journal Of Blood Medicine 2024, 15: 191-205. PMID: 38699197, PMCID: PMC11063465, DOI: 10.2147/jbm.s443380.Peer-Reviewed Original ResearchIntracranial hemorrhageIncidence rateInhibitor statusHemophilia AEstimate hazard ratiosAssociated with intracranial hemorrhageIncidence of intracranial hemorrhageMedian follow-up timeRisk of intracranial hemorrhageCurrent treatment landscapeIntracranial hemorrhage riskFollow-up timeTime-to-event analysisYears of ageProphylaxis statusHazard ratioTreatment landscapeGreater riskHepatitis CProphylactic treatmentPWHARate of mortalityIncreased riskRisk factorsATHNdataset
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply